What is B. Riley’s Forecast for RIGL Q1 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Analysts at B. Riley issued their Q1 2025 EPS estimates for Rigel Pharmaceuticals in a note issued to investors on Tuesday, March 4th. B. Riley analyst K. Patel anticipates that the biotechnology company will post earnings per share of $0.10 for the quarter. B. Riley currently has a “Neutral” rating and a $24.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals’ Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.38 EPS and FY2025 earnings at $0.84 EPS.

Several other analysts also recently commented on RIGL. Piper Sandler boosted their target price on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. StockNews.com downgraded shares of Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Cantor Fitzgerald boosted their target price on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 10th. Citigroup boosted their price objective on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.80.

Rigel Pharmaceuticals Stock Up 4.2 %

RIGL stock opened at $20.52 on Friday. The company has a market capitalization of $361.46 million, a price-to-earnings ratio of 146.58 and a beta of 1.35. Rigel Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $29.82. The firm has a 50 day moving average of $20.14 and a two-hundred day moving average of $18.43.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, March 4th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. The firm had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%.

Hedge Funds Weigh In On Rigel Pharmaceuticals

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in Rigel Pharmaceuticals during the 4th quarter valued at $63,000. Wells Fargo & Company MN increased its holdings in Rigel Pharmaceuticals by 44.5% in the 4th quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 2,648 shares during the period. SG Americas Securities LLC increased its holdings in Rigel Pharmaceuticals by 42.8% in the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 2,827 shares during the period. Graham Capital Management L.P. bought a new stake in Rigel Pharmaceuticals in the 4th quarter valued at $170,000. Finally, Integrated Quantitative Investments LLC bought a new stake in Rigel Pharmaceuticals in the 4th quarter valued at $181,000. 66.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Rigel Pharmaceuticals

In related news, CEO Raul R. Rodriguez sold 4,952 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total transaction of $103,595.84. Following the completion of the transaction, the chief executive officer now directly owns 243,854 shares in the company, valued at $5,101,425.68. This represents a 1.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP David A. Santos sold 2,125 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total transaction of $44,455.00. Following the transaction, the executive vice president now owns 53,500 shares of the company’s stock, valued at approximately $1,119,220. The trade was a 3.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,113 shares of company stock worth $190,644 in the last ninety days. 9.04% of the stock is currently owned by insiders.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.